Analysts expect Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) to report $-0.23 EPS on May, 14.They anticipate $0.46 EPS change or 66.67 % from last quarter’s $-0.69 EPS. After having $-0.39 EPS previously, Foamix Pharmaceuticals Ltd.’s analysts see -41.03 % EPS growth. The stock decreased 1.87% or $0.07 during the last trading session, reaching $3.68. About 286,817 shares traded. Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has declined 36.97% since April 16, 2018 and is downtrending. It has underperformed by 41.34% the S&P500.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Ratings Coverage

Among 4 analysts covering Foamix Pharma ( NASDAQ:FOMX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Foamix Pharma had 8 analyst reports since November 27, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, February 27 report. Cantor Fitzgerald maintained it with “Buy” rating and $15 target in Friday, March 8 report. The firm earned “Buy” rating on Tuesday, November 27 by Cantor Fitzgerald. As per Friday, March 1, the company rating was maintained by Cowen & Co. As per Monday, March 4, the company rating was maintained by H.C. Wainwright.

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France. The company has market cap of $200.07 million. The Company’s lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. It currently has negative earnings. The firm is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash.

More notable recent Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) news were published by: which released: “Foamix Announces $16 Million Investment by OrbiMed Nasdaq:FOMX – GlobeNewswire” on April 16, 2018, also with their article: “Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne – GlobeNewswire” published on March 07, 2019, published: “Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference – GlobeNewswire” on October 12, 2018. More interesting news about Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) were released by: and their article: “What Kind Of Share Price Volatility Should You Expect For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)? – Yahoo Finance UK” published on April 04, 2019 as well as ‘s news article titled: “Foamix – with Late-Stage Candidates in Acne and Rosacea – to Participate at American Academy of Dermatology Annual Meeting – GlobeNewswire” with publication date: February 26, 2019.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily …read more

Source:: Daily times


(Visited 1 times, 1 visits today)
$-0.23 EPS Expected for Foamix Pharmaceuticals Ltd. (FOMX) | Thorold News

Leave a Reply

Your email address will not be published. Required fields are marked *